Company Overview

ViewRay® Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdian® the world’s first MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s targeting accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who may not previously have been considered radiation therapy candidates. ViewRay believes MRIdian may improve the safety and efficacy of radiation therapy, potentially leading to improved patient outcomes with reduced side-effects from off-target radiation delivery.

Financial News

Date Title and Summary Additional Formats
Toggle Summary ViewRay Announces Conference Call and Webcast of Second Quarter 2019 Financial Results to be Held After Market on August 8, 2019
CLEVELAND , July 18, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its second quarter 2019 financial results. ViewRay will hold a conference call to discuss results on Thursday, August 8, 2019 at 4:30 p.m. ET / 1:30 p.m. PT .
Toggle Summary ViewRay Announces Appointment of Dr. Gail Wilensky to its Board of Directors
CLEVELAND , July 16, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced the appointment of Dr. Gail Wilensky to its Board of Directors, effective today. Dr. Wilensky has an extensive track record in healthcare as a policy leader, reimbursement expert, and board member.
Toggle Summary Leading Medical Physics Meeting to Feature More than 40 Presentations on ViewRay's MRIdian MRI-Guided Radiotherapy
Presentations Highlight MRIdian Clinical Experience with Real-Time On-Table Adaptive Radiotherapy at a Growing Number of Institutions Worldwide CLEVELAND , July 10, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian® System is the focus of more than 40
Toggle Summary World's First MRIdian Center Treats 1,000th Patient with MRI-Guided Radiation Therapy
Extensive Clinical Experience at Siteman Cancer Center Helps Further Adoption and Clinical Practice of MR-guided and On-Table Adaptive Radiation Therapy CLEVELAND , May 22, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the clinical team at Siteman Cancer Center at

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!
Click here for E-mail Alerts

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449

In Need of Customer Support? Contact

  Language Select